Table 3 Reduction of ACR by SGLT2 inhibitor in two groups with higher or lower values of baseline eGFR
0 M | n | Ipragliflozin | ||||||
|---|---|---|---|---|---|---|---|---|
1 M | n | 12 M | n | |||||
NRD (eGFR ≧ 60, n = 12) | ||||||||
ACR (mg/g Cr) | 163.1 (21.7, 945.8) | 12 | 118.5 (13.0, 366.5) | * | 12 | 114.1 (19.1, 539.4) | 12 | |
eGFR (ml/min/1.73 m2) | 72.7 (66.4, 80.9) | 12 | 71.0 (64.1, 80.3) | 12 | 72.7 (62.7, 83.6) | 12 | ||
Systolic BP (mmHg) | 133.4 ± 13.1 | 12 | 127.0 ± 13.7 | * | 12 | 123.2 ± 12.5 | * | 12 |
Diastolic BP (mmHg) | 83.8 ± 7.2 | 12 | 77.8 ± 5.7 | * | 12 | 76.8 ± 10.2 | 12 | |
BMI (kg/m2) | 28.6 (26.5, 31.1) | 12 | 28.5 (26.2, 31.5) | 12 | 28.5 (25.5, 29.7) | * | 12 | |
HbA1c (%) | 6.9 ± 0.5 | 12 | 6.7 ± 0.5 | * | 12 | 6.6 ± 0.6 | * | 12 |
HOMA-R | 4.5 (2.6, 5.6) | 9 | 3.8 (3.1, 5.1) | 12 | 3.6 (1.9, 4.2) | 11 | ||
Hb (g/dL) | 14.6 ± 1.8 | 11 | 15.1 ± 1.7 | * | 12 | 15.2 ± 1.4 | * | 12 |
RD (eGFR < 60, n = 9) | ||||||||
ACR (mg/g Cr) | 325.2 (111.0, 751.3) | 9 | 136.0 (62.2, 264.0) | * | 9 | 121.1 (95.9, 233.5) | 9 | |
eGFR (ml/min/1.73 m2) | 44.4 ± 8.2 | 9 | 42.3 ± 9.8 | 9 | 44.1 ± 9.2 | 9 | ||
Systolic BP (mmHg) | 129.3 ± 16.9 | 9 | 128.4 ± 10.0 | 9 | 128.3 ± 18.1 | 9 | ||
Diastolic BP (mmHg) | 79.3 ± 12.9 | 9 | 79.8 ± 10.9 | 9 | 75.4 ± 8.9 | 9 | ||
BMI (kg/m2) | 29.1 ± 8.1 | 9 | 28.9 ± 7.5 | 9 | 28.6 ± 7.5 | 9 | ||
HbA1c (%) | 6.7 ± 0.4 | 9 | 6.5 ± 0.2 | 9 | 6.6 ± 0.2 | 9 | ||
HOMA-R | 2.8 (2.8, 4.8) | 9 | 3.5 (2.3, 10.8) | 8 | 13.5 (6.5, 24.1) | 7 | ||
Hb (g/dL) | 13.6 ± 2.3 | 8 | 13.8 ± 2.1 | 8 | 14.0 ± 2.4 | 9 | ||